In 1953, Hopper proposed the idea of writing programs in words, rather than symbols, but she was told her idea would not work. Nevertheless, she continued working on an English-language compiler, and in 1956 her team was running FLOW-MATIC, the first programming language to use word commands. Unlike FORTRAN or MATH-MATIC, which used mathematical symbols, FLOW-MATIC used regular English words and was designed for data processing purposes. She also demonstrated how programs could be written in word-based languages other than English.
Was it worth it for them? Was it even for the phalanx of buyers, editors, and rubber-neckers in attendance? The jury is still out. The Council of Fashion Designers of America has yet to sell New York as an essential menswear stopover to the one group that would seem the most essential: New Yorkers.
What we found in our report is that there is no reform more essential to this cityâs economy than the Workforce Investment Act. The need for skill training has reached crisis proportions. Businesses ranging from software companies in Silicon Alley to small manufacturers in Long Island City are losing clients because they do not have qualified help. At the same time low-income job seekers aren't getting meaningful training as welfare time limits take effect.
The words are right on target, but they must be backed up with leadership, something we still have yet to see. We need a mayor, city council and a strong board voicing support for many of the goals set out in this plan. There must be an honest and intensive effort to recruit more private sector leaders to the board and there must be support from the top levels of government for there ever to be a chance of erecting a credible workforce system.
2) A direct connection to current incumbent worker training efforts. The plan rightly discusses integrating incumbent workers into the new workforce system under WIA. In a skill-driven era where employers are constantly in need of upgraded talent and workers are always in need of the latest knowledge, incumbent worker training is essential.
The criteria of a global city have varied over time and depending on the source;[3] common features include a high degree of urban development, a large population, the presence of major multinational companies, a significant and globalized financial sector, well-developed and internationally linked transportation infrastructure, local or national economic dominance, high quality educational and research institutions, and a globally influential output of ideas, innovations, or cultural products. Quintessential examples, based on most indices and research, include New York City, London, Paris, and Tokyo.
Monitoring and adjusting on the fly remain essential, but the process is now often guided by sophisticated analytical engines fueled by huge collections of patient records, including data on HIV genotypes, treatment histories, and responses, along with patient age, gender, race, and route of infection entry. Patient genotypes are certain to be added soon.
The virus continues to evolve, so the cocktails will remain "safe" and "effective" in any meaningful sense of those words only so long as we continue to prescribe them as directed by continuously updated databases. HIV can always gain time by killing its host more slowly; that gives it more time to evolve in today's host, and also more time for that host to infect his or her successor.
More fundamentally, we should now be using our experience with accelerated approval to take a closer look at the FDA's standard licensing protocols for all drugs. Those protocols, as the PCAST report notes, don't allow the participating doctors to systematically explore the many molecular factors that may determine why a drug performs well in some patients and not others. Most of those factors therefore end up being explored and understood after doctors prescribe the licensed drug and researchers assemble and analyze data from these sources. But those factors play an essential role in prescribing drugs safely and effectively, which means that many good drugs won't make it through the licensing process until enough of the relevant molecular factors have been identified.
df19127ead